Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.41 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | GSK3A | P49840 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | TOP2A | P11388 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22808271 | 0.87 | ALKBH5 (0.49) | ALKBH5FTOMEN1NPC1HCRTR1 | |
| SCHEMBL21168173 | 0.86 | ALKBH5 (0.55) | ALKBH5FTOMEN1NPC1HCRTR1 | |
| SCHEMBL22808276 | 0.84 | — | — | |
| SCHEMBL23046421 | 0.83 | ALKBH5 (0.58) | ALKBH5FTOMEN1NPC1HCRTR1 | |
| SCHEMBL12382854 | 0.80 | ALKBH5 (0.33) | ALKBH5FTOMEN1NPC1HCRTR1 | |
| SCHEMBL13100684 | 0.75 | ALKBH5 (0.62) | ALKBH5FTOKDM4EMAPTTOP2A | |
| SCHEMBL18848568 | 0.73 | CYP1A2 (0.42) | NPC1 | |
| SCHEMBL22808273 | 0.72 | DYRK1A (0.46) | ALKBH5FTOMEN1KMT2AGSK3A | |
| SCHEMBL14931058 | 0.70 | ALKBH5 (0.72) | ALKBH5FTOMEN1NPC1HCRTR1 | |
| SCHEMBL22808275 | 0.70 | PSMD14 (0.42) | ALKBH5FTOMEN1NPC1HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10937974-B2 | Organometallic compound, organic light-emitting device including the organometallic compound, and diagnostic composition including the organometallic compound | SAMSUNG ELECTRONICS CO; LTD. (KR) | 2021-03-02 | — | — | US | disclosed |
| US-10873039-B2 | Organometallic compound, organic light-emitting device including the organometallic compound, and diagnostic composition including the organometallic compound | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2020-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10873039-B2 | Organometallic compound, organic light-emitting device including the organometallic compound, and diagnostic composition including the organometallic compound | ORC3, LEF1, OCIAD1 | ALKBH5 2199/4885FTO 200/4885MEN1 41/4885 |
| US-10937974-B2 | Organometallic compound, organic light-emitting device including the organometallic compound, and diagnostic composition including the organometallic compound | ORC3, LEF1, OCIAD1 | ALKBH5 2199/4885FTO 200/4885MEN1 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.